Review Note
Last Update: 07/28/2024 09:22 PM
Current Deck: SK EBM Deck
Published
Fields:
Type
Double-blinded randomized controlled trial (2017)
Text
Trial: {{c1::MODIFY:Among patients received oral antibiotics for C. diff. infection, does bezlotozumab reduce rate of recurrence?}}
Conclusion: {{c2::Bezlotoxumab reduces rate of C. diff. recurrence.}}
Conclusion: {{c2::Bezlotoxumab reduces rate of C. diff. recurrence.}}
Population
(2655) adults with primary or recurrent C. diff. infection receiving PO vancomycin, fidaxomicin, or metronidazole
Primary endpoint
Recurrent infection
Secondary endpoint
Initial clinical cure and sustained cure (through 12 weeks)
Figure
Extra
The IDSA 2021 guidelines have a conditional recommendation to use bezlotoxumab in addition to standard of care antibiotics; this is largely limited by cost, and JHH generally does not recommend this except in multi-recurrent infection.
ankihub_id
ec2eff6f-f12e-43ab-9f62-a3fab1e16592
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: